SLIC-supervoxels-based response evaluation of osteosarcoma treated with neoadjuvant chemotherapy using multi-parametric MR imaging
- PMID: 32086578
- DOI: 10.1007/s00330-019-06647-1
SLIC-supervoxels-based response evaluation of osteosarcoma treated with neoadjuvant chemotherapy using multi-parametric MR imaging
Abstract
Objective: Histopathological examination (HPE) is the current gold standard for assessing chemotherapy response to tumor, but it is possible only after surgery. The purpose of the study was to develop a noninvasive, imaging-based robust method to delineate, visualize, and quantify the proportions of necrosis and viable tissue present within the tumor along with peritumoral edema before and after neoadjuvant chemotherapy (NACT) and to evaluate treatment response with correlation to HPE necrosis after surgery.
Methods: The MRI dataset of 30 patients (N = 30; male:female = 24:6; age = 17.6 ± 2.7 years) with osteosarcoma was acquired using 1.5 T Philips Achieva MRI scanner before (baseline) and after 3 cycles of NACT (follow-up). After NACT, all patients underwent surgical resection followed by HPE. Simple linear iterative clustering supervoxels and Otsu multithresholding were combined to develop the proposed method-SLICs+MTh-to subsegment and quantify viable and nonviable regions within tumor using multiparametric MRI. Manually drawn ground-truth ROIs and SLICs+MTh-based segmentation of tumor, edema, and necrosis were compared using Jacquard index (JI), Dice coefficient (DC), precision (P), and recall (R). Postcontrast T1W images (PC-T1W) were used to validate the SLICs+MTh-based necrosis. SLICs+MTh-based necrosis volume at follow-up was compared with HPE necrosis using paired t test (p ≤ 0.05).
Results: Active tumor, necrosis, and edema were segmented with moderate to satisfactory accuracy (JI = 62-78%; DC = 72-87%; P = 67-87%; R = 63-88%). Qualitatively and quantitatively (DC = 74 ± 9%), the SLICs+MTh-based necrosis area correlated well with the hypointense necrosis areas in PC-T1W. No significant difference (paired t test, p = 0.26; Bland-Altman plot, bias = 2.47) between SLICs+MTh-based necrosis at follow-up and HPE necrosis was observed.
Conclusion: The proposed multiparametric MRI-based SLICs+MTh method performs noninvasive assessment of NACT response in osteosarcoma that may improve cancer treatment monitoring, planning, and overall prognosis.
Key points: • The simple linear iterative clustering supervoxels and Otsu multithresholding-based technique (SLICs+MTh) successfully estimates the proportion of necrosis, viable tumor, and edema in osteosarcoma in the course of chemotherapy. • The proposed technique is noninvasive and uses multiparametric MRI to measure necrosis as an indication of anticancer treatment response. • SLICs+MTh-based necrosis was in satisfactory agreement with histological necrosis after surgery.
Keywords: Chemotherapy; Computer-assisted decision-making; Magnetic resonance imaging; Osteosarcoma; Treatment outcome.
Similar articles
-
Automatic segmentation and RECIST score evaluation in osteosarcoma using diffusion MRI: A computer aided system process.Eur J Radiol. 2020 Dec;133:109359. doi: 10.1016/j.ejrad.2020.109359. Epub 2020 Oct 20. Eur J Radiol. 2020. PMID: 33129104
-
Feasibility of multi-parametric magnetic resonance imaging combined with machine learning in the assessment of necrosis of osteosarcoma after neoadjuvant chemotherapy: a preliminary study.BMC Cancer. 2020 Apr 15;20(1):322. doi: 10.1186/s12885-020-06825-1. BMC Cancer. 2020. PMID: 32293344 Free PMC article.
-
Texture analysis for chemotherapy response evaluation in osteosarcoma using MR imaging.NMR Biomed. 2021 Feb;34(2):e4426. doi: 10.1002/nbm.4426. Epub 2020 Oct 20. NMR Biomed. 2021. PMID: 33078438
-
Utilisation of MR spectroscopy and diffusion weighted imaging in predicting and monitoring of breast cancer response to chemotherapy.J Med Imaging Radiat Oncol. 2015 Jun;59(3):268-77. doi: 10.1111/1754-9485.12310. Epub 2015 Apr 24. J Med Imaging Radiat Oncol. 2015. PMID: 25913106 Review.
-
Osteosarcoma.Cancer Treat Res. 2014;162:65-92. doi: 10.1007/978-3-319-07323-1_4. Cancer Treat Res. 2014. PMID: 25070231 Review.
Cited by
-
Imaging of pediatric bone tumors: A COG Diagnostic Imaging Committee/SPR Oncology Committee White Paper.Pediatr Blood Cancer. 2023 Jun;70 Suppl 4(Suppl 4):e30000. doi: 10.1002/pbc.30000. Epub 2022 Oct 17. Pediatr Blood Cancer. 2023. PMID: 36250990 Free PMC article.
-
Nanoparticles and bone microenvironment: a comprehensive review for malignant bone tumor diagnosis and treatment.Mol Cancer. 2024 Nov 1;23(1):246. doi: 10.1186/s12943-024-02161-1. Mol Cancer. 2024. PMID: 39487487 Free PMC article. Review.
References
-
- Landis SH, Murray T, Bolden S, Wingo PA (1999) Cancer statistics, 1999. CA Cancer J Clin 49:8–31. https://doi.org/10.3322/canjclin.49.1.8 - DOI - PubMed
-
- Bacci G, Picci P, Ferrari S et al (1993) Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin. Cancer 72:3227–3238. https://doi.org/10.1002/1097-0142(19931201)72:11<3227::AID-CNCR282072... - DOI - PubMed
-
- Bacci G, Briccoli A, Ferrari S et al (2001) Neoadjuvant chemotherapy for osteosarcoma of the extremity: long-term results of the Rizzoli’s 4th protocol. Eur J Cancer 37:2030–2039. https://doi.org/10.1016/S0959-8049(01)00229-5 - DOI - PubMed
-
- Wittig JC, Bickels J, Priebat D et al (2002) Osteosarcoma: a multidisciplinary approach to diagnosis and treatment. Am Fam Physician 65:1123–1132. https://doi.org/10.1111/j.1529-8019.2010.01352.x - DOI - PubMed
-
- Wang C, Du L, Si M et al (2013) Noninvasive assessment of response to neoadjuvant chemotherapy in osteosarcoma of long bones with diffusion-weighted imaging: an initial in vivo study. PLoS One 8:e72679. https://doi.org/10.1371/journal.pone.0072679 - DOI - PubMed - PMC
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical